AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 41 min read$UTHR

United Therapeutics 3Q 2026: Revenue $832.5M, Net income $258.6M, EPS $5.71— 10-Q Summary

United Therapeutics reported 3Q 2026 revenue of $832.5M, up 4.1% YoY, but net income fell 23.6% to $258.6M. EPS declined 20.3% to $5.71. Tyvaso DPI sales grew 13%, while nebulized Tyvaso dropped 12%. FDA accepted applications for nebulized Tyvaso and ralinepag, with decisions in 2027. Three xenograft facilities are complete, with LungFX launch planned for 2027.

Original reporting
tradingview.com
Published Nov 4, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
United Therapeutics 3Q 2026: Revenue $832.5M, Net income $258.6M, EPS $5.71— 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$UTHRBearishHigh
01

Why it matters

The earnings miss may trigger a short‑term decline, but upcoming FDA approvals could provide upside catalysts.

02

Market read

Earnings release is the primary catalyst for UTHR stock movement today.

03

What to watch

FDA approvals for new indications could offset short‑term earnings weakness.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

United Therapeutics filed its 10‑Q for Q3 2026, providing the first public disclosure of the quarter's financials.

Company-level read

Ticker impact

$UTHRBearishHigh confidence
Context

United Therapeutics posted Q3 2026 results with revenue up 4.1% YoY but net income down 23.6% and EPS down 20.3%.

Expected impact

downward pressure as the market prices in the earnings miss

Evidence & confidence

Revenue growth was modest while profitability declined sharply, which typically triggers a sell‑off.

Market effects

Sector

Pulmonary‑hypertension drug makers may see heightened scrutiny on profit margins.

Regional

Limited to U.S. biotech sector.

Global

Minimal beyond sector peers.

Counterpoint

What could challenge this read

Some investors may view the revenue growth as a positive tailwind and buy on dip.

Key entities

  • company
    United Therapeutics

    Biopharma focused on pulmonary hypertension therapies.

Read at source← All news

StoryUnited Therapeutics reports Q3 2026 revenue up 4% to $832.5M, net income down 24%

Also covered by

4 outlets

Related articles

NOV 4
$UTHRMedAI 8/10

United Therapeutics Q3 2026 Revenue Up 4%, Net Income Falls 24%

United Therapeutics (UTHR) reported Q3 2026 revenue of $832.5M, up 4% YoY, but net income fell 24% to $258.6M due to higher R&D spending and competitive pressures. EPS declined 20% to $5.71. Tyvaso DPI sales rose 13%, while nebulized Tyvaso fell 12%. R&D expenses surged 119% to $279.2M, partly due to the Thymmune acquisition. The company repurchased shares under a 10b5-1 plan and a $2B repurchase program.

minichart.com.sg2 min
NOV 4
$UTHRHigh

United Therapeutics buys out Pfizer royalty for $525 million

United Therapeutics (UTHR) will pay $525M to Pfizer's Arena subsidiary to end royalty obligations on ralinepag, a drug for pulmonary arterial hypertension. The FDA is reviewing an application for oral ralinepag, with a decision expected by June 24, 2027. United Therapeutics acquired rights to ralinepag in 2018 and is also developing an inhaled version. According to the company, the transaction reflects confidence in the drug's revenue potential.

investing.com1 min